CytomX Therapeutics, Inc. CTMX
Set alert
At close · Oct 30
After hours · Oct 30, 5:42 PM ET
- YTD
- -45.07%
- 1 year
- -29.73%
- Open
- 2.28
- Prev close
- 2.29
- Mkt cap
- 509.88M
- Vol
- 4.94M
- Avg vol
- 3.48M
- EPS
- -0.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.21
- High
- 2.36
- Forward P/E
- -9.74
- Beta
- 2.48
- Short ratio
- 1.78
- Inst. own
- 75.69%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.92
- 200-d avg
- 3.77
- 1y target
- 13.67
5D chart
Signals (62)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:10 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:55 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:30 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| RSI: Overbought | Oct 28, 11:25 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:00 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:35 PM | 6 days ago |
| RSI: Oversold | Oct 26, 11:05 AM | 6 days ago |
News
3 days ago globenewswire.com
CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it…
2 weeks ago defenseworld.net
CytomX Therapeutics (NASDAQ:CTMX) Reaches New 1-Year Low – Should You Sell?
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) shares reached a new 52-week low on Wednesday. The company traded as low as $2.32 and last traded at $2.33, with a volume of 5,223,013…
1 month ago seekingalpha.com
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago globenewswire.com
CytomX Therapeutics to Present at Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that…
2 months ago globenewswire.com
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H…
2 months ago defenseworld.net
AWM Investment Company Inc. Acquires Shares of 150,000 CytomX Therapeutics, Inc. $CTMX
AWM Investment Company Inc. acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ: CTMX) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor…
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
2 months ago defenseworld.net
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX
Bank of America Corp DE boosted its position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 1,064.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange…
2 months ago seekingalpha.com
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limiting drug activity in healthy tissue. Their lead asset is Varseta-M, which has interesting early…
-
2 months ago benzinga.com
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.
2 months ago seekingalpha.com
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics NASDAQ: CTMX said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while…
2 months ago zacks.com
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to break-even earnings per share a year ago.
-
2 months ago benzinga.com
CytomX Therapeutics Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $1.418M Miss $12.308M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. The company reported quarterly sales of $1.418…
2 months ago globenewswire.com
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - -…
3 months ago globenewswire.com
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the…
3 months ago globenewswire.com
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it…
3 months ago defenseworld.net
ADAR1 Capital Management LLC Sells 872,579 Shares of CytomX Therapeutics, Inc. $CTMX
ADAR1 Capital Management LLC reduced its position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 20.4% during the undefined quarter, according to the company in its most recent 13F filing with the…
3 months ago globenewswire.com
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the…
3 months ago zacks.com
CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 months ago seekingalpha.com
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
5 months ago globenewswire.com
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY ® and Regeneron's Veloci-Bi ® platforms -
5 months ago seekingalpha.com
CytomX Therapeutics: Cashed Up With Catalysts Ahead
In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M,…
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
7 months ago benzinga.com
Crude Oil Down 4%; Dollar Tree Earnings Top Views
Crude Oil Down 4%; Dollar Tree Earnings Top Views
7 months ago benzinga.com
Nebius Group, CytomX Therapeutics, National Storage Affiliates Trust And Other Big Stocks Moving Higher On Monday
Dow Jones index up 500 points; Nebius Group NV shares rise 12.7% on AI agreement with Meta Platforms; several other stocks record gains.
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
7 months ago benzinga.com
Market-Moving News for March 16th
NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated Capacity Across Multiple Locations Using NVIDIA Vera Rubin Platform Starting Early 2027 CTMX: 70%
7 months ago benzinga.com
Earnings Scheduled For March 16, 2026
Earnings Scheduled For March 16, 2026
10 months ago benzinga.com
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
12 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million.
1 year ago benzinga.com
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
1 year ago benzinga.com
Why Gap Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Why Gap Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
-
2 years ago benzinga.com
Etsy Reports Downbeat Earnings, Joins Fastly, DoorDash And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Etsy Reports Downbeat Earnings, Joins Fastly, DoorDash And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
-
2 years ago benzinga.com
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.
-
2 years ago benzinga.com
Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings for its fis
-
2 years ago benzinga.com
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Earnings Scheduled For August 8, 2023
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly earnings at $0.21 per share on revenue of $1.48 billion.
-
3 years ago benzinga.com
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top…